COVID-19
SARS-CoV-2 (2019-nCoV)는 highly-pathogenic β-coronavirus로 인해 발생한 3번째 질병입니다. 이는 종들 사이의 바이러스 감염주기, 바이러스 복제에 관련된 세포 경로, 선천 혹은 후천 면역 반응에 대해 심도 있는 지식을 필요로 하는 것을 의미합니다. 이러한 근본적인 질문에 대한 답변은 예방백신은 물론 안전하고 효율적인 치료법 설계에 도움이 될 것입니다.
아래 동영상으로도 Invivogen의 제품을 확인할 수 있습니다.
COVID-19-Related Products
*제품을 클릭하시면 상세 페이지를 확인하실 수 있습니다.
COVID-19-Related Genes (Vector)
COVID-19-Related Antibodies
Product name | QUALITY CONTROL | Unit size | Cat.no |
Anti-Spike-RBD hIgG1 (CR3022) | Functionality validated by ELISA using a coated Spike-RBD-His fusion peptide | 100 µg | srbd-mab1 |
Anti-Spike-RBD hIgA1 (CR3022) | Functionality validated by ELISA using a coated Spike-RBD-His fusion peptide
| 100 µg | srbd-mab6 |
Anti-Spike-RBD hIgM (CR3022) | Functionality validated by ELISA using a coated Spike-RBD-His fusion peptide
| 100 µg | srbd-mab5 |
Anti-Spike-RBD hIgG1NQ (CR3022) | Functionality validated by ELISA using a coated Spike-RBD-His fusion peptide
| 100 µg | srbd-mab12 |
Anti-Spike-RBD mIgG2a (CR3022) | Functionality validated by ELISA using a coated Spike-RBD-His fusion peptide
| 100 µg | srbd-mab10 |
Anti-Spike-RBD mIgG1e3 (CR3022) | Functionality validated by ELISA using a coated Spike-RBD-His fusion peptide
| 100 µg | srbd-mab15 |
Anti-hIL6R-To-hIgG1 | Functionally validated using HEK-Blue™ IL-6 cellular assays | 100 µg | hil6rto-mab1 |
Anti-hIL6R-To-hIgG1NQ | Functionally validated using HEK-Blue™ IL-6 cellular assays
| 100 µg | hil6rto-mab12 |
Anti-hIL6R-To-hIgA2 | Functionally validated using HEK-Blue™ IL-6 cellular assays
| 100 µg | hil6rto-mab7 |
Anti-Spike-RBD-hIgG1-HRP | Functionality validated by ELISA using a coated Spike-RBD-His fusion peptide
| 100µg | srbd-mab1-hrp |
Anti SARS-CoV-2 RBD mAb (Clone H4) | Functionality validated by ELISA using a coated Spike-RBD-His fusion peptide
| 100 µg | cov2rbdc1-mab1 |
Anti SARS-CoV-2 RBD mAb (Clone B38) | Functionality validated by ELISA using a coated Spike-RBD-His fusion peptide
| 100 µg | cov2rbdc2-mab1 |
Anti SARS-CoV-2 Nucleocapsid mAb (clone CR3018) | Functionality validated by ELISA using a coated Spike-RBD-His fusion peptide
| 100 µg | covn-mab1 |
COVID-19-Related Proteins
COVID-19-Related Inhibitors
Other COVID-19-Related Products
Poly(I:C): TLR3 agonist
3p-hpRNA: RIG-I agonist
pFUSE-Fc plasmids: Cloning vectors for the generation of Fc-Fusion proteins
Plasmid | Cloning site / Gene | Fc Region | Isotypes Available |
C-terminal Fc fusions | | | |
pFUSE-Fc | Cloning sites | Native, No introns | - Human IgG1, 2, 3, 4 |
- Mouse IgG1, 2a, 2b, 3 |
- Rabbit IgG |
- Rat IgG2b |
pINFUSE-Fc | Cloning sites | Native, With introns | - Human IgG1, 2, 3, 4 |
- Mouse IgG2b |
pFUSE-Fc engineered | Cloning sites | Engineered, No introns | - Human IgG1, 2, 4 |
- Mouse IgG1, 2a |
pFUSE-Lucia-Fc | Lucia secreted luciferase - Cloning sites | Native, No introns | - Human IgG1 |
- Mouse IgG2a |
pFUSE-SEAP-Fc | SEAP | Native, No introns | - Human IgG1, 2, 3, 4 |
- Mouse IgG2a, 2b, 3 |
- Rabbit IgG |
- Rat IgG2b |
N-terminal Fc fusions |
|
pFUSEN-Fc | Cloning sites | Native, No introns | - Human IgG1,2 |
- Mouse IgG2a |
pFUSEN-Fc engineered | Cloning sites | Engineered, No introns | - Human IgG1 |
|
pFUSEN-Lucia-Fc | Lucia secreted luciferase - Cloning sites | Native, No introns | - Human IgG1, 2 |
- Mouse IgG2a |
pFUSEN-Lucia-Fc engineered | Lucia secreted luciferase - Cloning sites | Engineered, No introns | - Human IgG1 |
|
Antibody generation
pFUSE | Constatnt Region | | Gene |
pFUSE-CLIg family | Light chain expression plasmid | multiple cloning site (MCS) | |
pFUSE-CHIg family | Heavy chain expression plasmid | multiple cloning site (MCS) | |
pFUSE-Lucia-CHIg | heavy chain (CH) of human, mouse, rabbit | multiple cloning site (MCS) | Lucia secreted luciferase |
Engineered pFUSE-CHIg | heavy chain (CH) of the human IgG1 | multiple cloning site (MCS) | |
pTRIOZ | Unit size | Cat.no | Heavy chain cassette | Light chain cassette |
pTRIOZ-hIgG1 | 20 µg | ptrioz-higg1 | Human IgG1 | Human kappa |
pTRIOZ-hIgG4 (S228P) | 20 µg | ptrioz-higg4sp | Human IgG4 (S228P) | Human kappa |
pTRIOZ-mIgG1e2 | 20 µg | ptrioz-migg1e2 | Murine IgG1e2 | Murine kappa |
pTRIOZ-mIgG2a | 20 µg | | Murine IgG2a | Murine kappa |
Vaccine adjuvants
Alum & Emulsions | Generate depots that trap antigens at the injection site for a sustained stimulation of the immune system through an increased recruitment and activation of antigen presenting cells (APCs) |
PRR agonists | Effectively activate a local innate immune response, predominantly targeting the APCs, and consequently influencing the necessary adaptive immune responses. Members of nearly all of the PRR families are potential targets for adjuvants. |
학술 문의 Tel. 031-728-3236 E-mail. technical@dawinbio.com
COVID-19
SARS-CoV-2 (2019-nCoV)는 highly-pathogenic β-coronavirus로 인해 발생한 3번째 질병입니다. 이는 종들 사이의 바이러스 감염주기, 바이러스 복제에 관련된 세포 경로, 선천 혹은 후천 면역 반응에 대해 심도 있는 지식을 필요로 하는 것을 의미합니다. 이러한 근본적인 질문에 대한 답변은 예방백신은 물론 안전하고 효율적인 치료법 설계에 도움이 될 것입니다.
아래 동영상으로도 Invivogen의 제품을 확인할 수 있습니다.
COVID-19-Related Products
*제품을 클릭하시면 상세 페이지를 확인하실 수 있습니다.
• SARS-CoV-2 Cellular Receptor Genes
• SARS-CoV-2 Structural Genes
• Viral RdRp Inhibitor
- Remdesivir
• Type I IFN Inducers
- Poly(I:C)
• Anti-SARS-CoV-2 Antibodies
• Fc-Fusion
COVID-19-Related Proteins
• Spike
- Bafilomycin A1
• Antibody Generation
- pFUSE
• Nucleocapsid
• Human ACE2
• Vaccine Adjuvants
- Alum, emulsions, and PRR agonists
COVID-19-Related Genes (Vector)
COVID-19-Related Antibodies
(clone CR3018)
COVID-19-Related Proteins
COVID-19-Related Inhibitors
Other COVID-19-Related Products
Poly(I:C): TLR3 agonist
3p-hpRNA: RIG-I agonist
pFUSE-Fc plasmids: Cloning vectors for the generation of Fc-Fusion proteins
pFUSE-Fc
Cloning sites
Native, No introns
pFUSE-SEAP-Fc
SEAP
Native, No introns
Antibody generation
Vaccine adjuvants
학술 문의 Tel. 031-728-3236 E-mail. technical@dawinbio.com